Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) - and Quality of Life (QoL) in Elderly Patients (≥60 Years) With Ph+ Chronic Myeloid Leukemia (CML) and MR3.0 / MR4.0 Stable Molecular Response

NCT02326311 is registered in ClinicalTrials.gov with Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia as lead sponsor.

NCT NCT02326311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02326311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) - and Quality of Life (QoL) in Elderly Patients (≥60 Years) With Ph+ Chronic Myeloid Leukemia (CML) and MR3.0 / MR4.0 Stable Molecular Response
Lead sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase
Phase 3
Overall status
Completed
Start date
June 10, 2015
Completion date
May 29, 2024
Enrollment
229 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, chronic myeloid